Q-omics provides the consensus-scored RBMXP4 profile across patient tissues and cancer cell-line models. RBMXP4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RBMXP4 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, RBMXP4 RNA expression shows 15,552 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, BRCA, and UVM as cancer lineages where RBMXP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMXP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMXP4 survival associations across molecular data types. RBMXP4 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMXP4 RNA expression–survival associations across cancer types. High RBMXP4 expression shows unfavorable associations in STAD, but favorable associations in MESO, READ, PAAD, SARC and ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .021). Together, the overview and detailed table identify STAD as the clearest survival context for RBMXP4 RNA expression.
This table summarizes RBMXP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMXP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMXP4 shows lower tumor expression in BRCA, LUSC, LUAD and KICH and higher tumor expression in CHOL and KIRC. The BRCA box plot shows higher RBMXP4 RNA expression in normal versus tumor tissue (log2 FC = −0.551, t-test p < 0.001).
This table shows molecular features associated with RBMXP4 in patient tissues and cancer cell lines. In patient samples, RBMXP4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
